About Locus Biosciences
Locus Biosciences is a Healthcare company based in Raleigh (United States) founded in 2015. Developer of therapeutics for infectious disease and inflammatory indications. Locus Biosciences has raised $67.33 million across 12 funding rounds from investors including Tencent, Illumina and Hercules Capital. The company has 74 employees. Locus Biosciences has completed 1 acquisition, including EpiBiome. Locus Biosciences offers products and services including LOCUS Platform and LBP-EC01. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its legal entity is LOCUS BIOSCIENCES, INC. Its competitors include Beam Therapeutics, Spero Therapeutics and eGenesis; 3 of its 3 listed competitors have raised funding.
Company details
Locus Biosciences was founded in 2015 and is headquartered in Raleigh, United States. Operations focus on the biotechnology sector, where a platform is utilized to design and deliver custom CRISPR-Cas systems targeting specific bacteria. Antimicrobials for infectious diseases are enabled through this approach, alongside therapeutics for inflammatory indications. Research and development activities are centered on advancing precision treatments in these areas.
- Headquarters Raleigh, United States
- Employees 74
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website locus-bio.com
- Social LinkedIn X
- Legal Name Locus Biosciences, Inc
Products & Services of Locus Biosciences
Locus Biosciences offers a comprehensive portfolio of products and services, including LOCUS Platform and LBP-EC01.
AI-driven system for designing engineered bacteriophage therapies for infections.
Targets E. coli infections through precision bacteriophage therapeutics.
Funding Insights of Locus Biosciences
Locus Biosciences has successfully raised a total of $67.33M across 12 strategic funding rounds. The most recent funding activity was a Grant round of $23.9 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $67.33M
- Total Rounds 12
- Last Round Grant — $23.9M
- First Round $75,000
(Feb 2016)
- Investors Count 9
Latest 10 of 12 funding rounds of Locus Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | $23.9M | Grant | – | – | |
| May 2022 | $35M | Series B | – | Viking Global Investors, Johnson & Johnson Innovation | |
| Oct 2021 | Debt – Conventional | – | – | ||
| Nov 2020 | $20M | Debt – Conventional | – | – | – |
| Oct 2019 | Series A | – | Illumina | – | |
| Nov 2017 | $19M | Series A | – | Artis Ventures | |
| Oct 2017 | $7M | Series A | – | – | – |
| Jul 2017 | $5M | Series A | – | Tencent | |
| Dec 2016 | $350,000 | Debt – Conventional | – | – | – |
| Apr 2016 | $250,000 | Debt – Venture | – | – |
9 investors in total: 9 institutional.
Investors in Locus Biosciences
Locus Biosciences has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Tencent, Illumina and Hercules Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Early-stage startups are invested in by Artis Ventures. | av.co | San Francisco, United States | ||
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Early-stage startups are invested in by sector-agnostic VC firm. | abstractvc.com | San Francisco, United States | ||
Biotech startups are incubated and funded in North Carolina. | 1984 | ncbiotech.org | Durham, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
| jnjinnovation.com | ||||
Value-added internet, mobile, and telecom services are provided in China. | 1998 | tencent.com | Shenzhen, China | |
Developer of technologies for analysis of genetic variation and function | 1993 | illumina.com | San Diego, United States |
Investor details for Locus Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Locus Biosciences
13 people are tracked at Locus Biosciences (7 in leadership, 2 in board & advisors, 4 in team); the tracked headcount is 74.
| Name | Role | Group |
|---|---|---|
Wendy Summers | VP of Pharmaceutical Operations & Technology | Leadership |
Joseph Nixon | Chief Financial Officer | Leadership |
Paul Kim | Chief Development Officer | Leadership |
Nathan Macgregor | Associate Director of Quality | Leadership |
Paul Garofolo | CEO | Leadership |
Jamie Kime | VP of Clinical Operations & CMC Operations | Leadership |
Jeffrey Meisner | Senior Director, Development And Program Lead | Leadership |
Bary Bailey | Director | Board & advisors |
Stuart Peterson | Director | Board & advisors |
Joshua Goodman | Accounting Manager | Team |
Aaron Le | Senior Project Coordinator | Team |
Barrington Briggs | Staff Accountant | Team |
Ryan O’Grady | Development Technologist | Team |
Complete people profiles for Locus Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Locus Biosciences
Locus Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include EpiBiome.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small-molecule antibiotics are developed for agriculture and human health. | epibiome.com | San Francisco, United States | 2013 | Jul 2018 | •••• |
Complete acquisition details for Locus Biosciences
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Locus Biosciences
4 dated milestones of Locus Biosciences across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Locus Biosciences is founded.
- Funding First funding round of $75K.
- Acquisition Acquires EpiBiome.
- Funding Latest funding round, Grant, of $23.9M.
Competitors of Locus Biosciences
Locus Biosciences has 3 listed competitors in our database, 3 of them funded. They include Beam Therapeutics, Spero Therapeutics and eGenesis.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beamtx.com | 2017 | Cambridge, United States | $222M | 340 | Developer of gene therapy using CRISPR base editing to treat diseases | |
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| egenesisbio.com | 2015 | Cambridge, United States | $481.42M | 94 | Gene transplantation platform for humanizing pig cells is developed. |
Detailed competitors of Locus Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Locus Biosciences
The website of Locus Biosciences (locus-bio.com) receives about 6.5K visits a month and ranks #3,318,634 among all websites worldwide, #4,363 in Biotechnology and Pharmaceuticals.
- Monthly visits6.5K
▲ 7.6% vs previous month
- Unique visitors2.5K
per month
- Global rank#3,318,634
among all websites
- Category rank#4,363
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.6
- Average visit18 sec
- DevicesDesktop 30% · Mobile 70%
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Locus Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Locus Biosciences
Complete news archive for Locus Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Locus Biosciences
Locus Biosciences was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Locus Biosciences is headquartered in Raleigh, United States. It is registered at Raleigh, North Carolina, United States.
Locus Biosciences is a funded company, having raised a total of $67.33M across 12 funding rounds to date. The company's 1st funding round was a Debt – Venture of $250K, raised on Feb 2016.
Locus Biosciences has 74 employees.
Locus Biosciences was founded in 2015 and is headquartered in Raleigh, United States. Operations focus on the biotechnology sector, where a platform is utilized to design and deliver custom CRISPR-Cas systems targeting specific bacteria. Antimicrobials for infectious diseases are enabled through this approach, alongside therapeutics for inflammatory indications. Research and development activities are centered on advancing precision treatments in these areas.
Locus Biosciences's top competitors include Spero Therapeutics, eGenesis and Beam Therapeutics.
Locus Biosciences offers LOCUS Platform and LBP-EC01.
Locus Biosciences has made 1 acquisition, including EpiBiome.
Locus Biosciences has 9 investors. Key investors include Tencent, Illumina, Hercules Capital, HHS, and NCBiotech.
Locus Biosciences operates through Locus Biosciences, Inc.